本文選題：多發(fā)性硬化　切入點(diǎn)：人臍帶血間充質(zhì)干細(xì)胞　出處：《山東醫(yī)藥》2017年37期

【摘要】：目的對(duì)比觀察不同劑量人臍帶間充質(zhì)干細(xì)胞(hUC-MSC)移植治療多發(fā)性硬化(MS)的臨床效果。方法將60例MS患者隨機(jī)均分為A、B、C、D組。從足月健康新生兒臍帶中提取hUC-MSC;各組均采用BEAM方案(卡莫司汀、替尼泊苷、阿糖胞苷、美法侖)進(jìn)行預(yù)處理。A、B、C組采用腰椎穿刺術(shù)經(jīng)蛛網(wǎng)膜下腔分別注射hUCMSC 1.5×10~6/kg、7.5×10~6/kg、15×10~6/kg,D組給予相同體積生理鹽水。每2周移植1次,共移植3次。治療前后采用擴(kuò)展致殘狀況評(píng)分量表(EDSS)對(duì)患者神經(jīng)功能缺損程度進(jìn)行評(píng)分,采用MR檢查頭顱、脊髓病灶數(shù)量及病灶體積變化,統(tǒng)計(jì)患者治療期間發(fā)生的不良反應(yīng)。結(jié)果與治療前比較,治療后A、B、C組EDSS較D組低(P均0.05),且C組B組A組,兩兩比較差異有統(tǒng)計(jì)學(xué)意義(P均0.05)。治療后A、B、C組病灶數(shù)目及體積均較D組小(P均0.05),且C組B組A組,兩兩比較差異有統(tǒng)計(jì)學(xué)意義(P均0.05)。治療過(guò)程中B、D組各出現(xiàn)1例低等發(fā)熱,經(jīng)對(duì)癥處理后均于3 d內(nèi)恢復(fù)正常。結(jié)論在常規(guī)抗炎治療基礎(chǔ)上加hUC-MSC移植治療能改善MS患者的臨床癥狀;且在≤15×106/kg范圍內(nèi),移植劑量越高治療效果越佳。
[Abstract]:Objective to observe the clinical effect of different doses of human umbilical cord mesenchymal stem cells (hUC-MSC) in the treatment of multiple sclerosis (MS). Using the BEAM scheme (Carmosine, Teniposide, cytarabine, mefalen) pretreatment. Group C received lumbar puncture via subarachnoid space injection of hUCMSC 1.5 脳 10 ~ 6 / kg ~ 7.5 脳 10 ~ (-6) 路kg ~ (-1) 路kg ~ (-1) 脳 10 ~ (-6)% 路kg ~ (-1) 路kg ~ (-1) 路kg ~ (-1) 路kg ~ (-1) / kg ~ (15 脳 10 ~ (6)) 路kg ~ (-1) 路kg ~ (-1) 路kg ~ (-1). Before and after treatment, the degree of neurological impairment was evaluated by EDSS, the number of head, spinal cord lesions and the volume of lesions were examined by Mr. Results compared with those before treatment, the EDSS of group A was lower than that of group D (P 0.05), and that of group C was lower than that of group B (P 0.05), and that of group B (group A) was higher than that of group C (P < 0.05). After treatment, the number and volume of lesions in group A were significantly lower than those in group D, and there were significant differences between group A and group C (P < 0.05). During the course of treatment, there was one case of low fever in group B and group D, and the difference was significant in group A (P < 0.05), and there was a significant difference between group A and group C (P < 0.05). Conclusion the clinical symptoms of MS patients can be improved by hUC-MSC transplantation on the basis of routine anti-inflammatory therapy, and in the range of 鈮，

本文編號(hào)：1681489